San Antonio Breast Cancer Symposium (SABCS)

Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual, invasive, early breast cancer after neoadjuvant therapy: a randomized phase 3 trial (DESTINY-Breast05)

Trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator’s choice of chemotherapy in patients with hormone receptor–positive (HR+), HER2-low metastatic breast cancer whose disease has progressed on endocrine therapy in the metastatic setting: a randomized, global, phase 3 trial (DESTINY-Breast06)

Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)

Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: a phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)

Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study

Updated Results From DESTINY-Breast01, a Phase 2 Trial of Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Breast Cancer

Novel approach to HER2 quantification: digital pathology coupled with AI-based image and data analysis delivers objective and quantitative HER2 expression analysis for enrichment of responders to trastuzumab deruxtecan (T-DXd; DS-8201), specifically in HER2-low patients

Real-world clinical outcomes of patients with BRCA-mutated (BRCAm) HER2-negative metastatic breast cancer: a CancerLinQ® study

A real-world evidence study of treatment patterns among patients with HER2-positive metastatic breast cancer

Ceralasertib in combination with olaparib in patients with advanced breast cancer: results of phase 1 expansion cohorts